Scarica l'app Stockscreener
2.23
0.00%
0.00
Dopo l'orario di chiusura:
2.27
0.04
+1.79%
Cervomed Inc Borsa (CRVO) Ultime notizie
HC Wainwright & Co. Downgrades CervoMed (CRVO) - MSN
Research Analysts Issue Forecasts for CervoMed Q1 Earnings - Defense World
CervoMed (NASDAQ:CRVO) Cut to Hold at Brookline Capital Management - Defense World
CervoMed price target lowered to $4 from $45 at Roth MKM - Yahoo Finance
CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CervoMed Awards Key Executive Stock Options in Strategic Talent Acquisition Move - StockTitan
CervoMed's dementia drug fails mid-stage trial, shares slump - MSN
Chardan Capital Downgrades CervoMed (CRVO) - MSN
What Was Behind CervoMed’s Lewy Body Disappointment? - News & Insights
CervoMed announces RewinD-LB Phase 2b did not meet primary endpoint - Yahoo Finance
Morgan Stanley cuts CervoMed to Underweight on disappointing trial results By Investing.com - Investing.com UK
CervoMed shares await clarity with open-label extension data and French Phase 2a results - Investing.com Canada
CervoMed stock downgraded to Hold as Phase 2b trial disappoints By Investing.com - Investing.com Canada
CervoMed shares rating downgraded after trial data disappoints - Investing.com
Jones Trading Downgrades CervoMed (CRVO) - MSN
CervoMed's dementia drug fails to meet mid-stage trial goals - MSN
CervoMed stock downgraded to Hold as Phase 2b trial disappoints - Investing.com
CervoMed shares rating downgraded after trial data disappoints By Investing.com - Investing.com Canada
CervoMed’s stock craters 77% after failed trial of treatment for rare brain disease - MSN
CervoMed's Dementia Candidate Fails In Mid-Stage Study, Stock Plummets - Yahoo Finance
US Small Business Optimism Hits 3-Year High As Election Results 'Signal A Major Shift' - Benzinga
CervoMed Shares Slide to All-Time Low After Study Failure - MarketWatch
CervoMed’s dementia drug fails to meet mid-stage trial goals - 1470 & 100.3 WMBD
Late-stage plans on ice as CervoMed's oral drug fails dementia study - FirstWord Pharma
CervoMed's ex-Vertex drug fails to reduce dementia symptoms in phase 2 trial - Fierce Biotech
CervoMed Inc. Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies - Marketscreener.com
CervoMed tumbles after dementia drug fails to meet mid-stage trial goals - XM
CervoMed Faces Setback in Phase 2b Trial - TipRanks
CervoMed Phase 2b Study of Neflamapimod Misses Main Endpoints - MarketWatch
CervoMed Announces Topline Data from RewinD-LB Phase 2b - GlobeNewswire
HC Wainwright Predicts CervoMed FY2024 Earnings - MarketBeat
CervoMed (NASDAQ:CRVO) Coverage Initiated at Roth Mkm - Defense World
Research Analysts Set Expectations for CervoMed Q4 Earnings - Defense World
Roth/MKM sets stock target on CervoMed, buy rating on strong trial results - Investing.com Nigeria
HC Wainwright & Co. Initiates Coverage of CervoMed (CRVO) with Buy Recommendation - MSN
CervoMed (NASDAQ:CRVO) Coverage Initiated by Analysts at Roth Mkm - MarketBeat
What is HC Wainwright's Estimate for CervoMed Q4 Earnings? - MarketBeat
CervoMed Enhances Transparency with Key Information Access - TipRanks
CervoMed (NASDAQ:CRVO) Given “Buy” Rating at D. Boral Capital - Defense World
Morgan Stanley Initiates Coverage of CervoMed (CRVO) with Overweight Recommendation - MSN
FDA grants Orphan Drug status to CervoMed's dementia drug By Investing.com - Investing.com South Africa
CervoMed’s stock rises as FDA grants orphan drug status to dementia drug - Pharmaceutical Technology
CervoMed Stock Surges On FDA Orphan Drug Nod For FTD Treatment: Retail Optimism Rekindled - MSN
CervoMed's (CRVO) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
CervoMed stock gains on FDA orphan tag (CRVO:NASDAQ) - Seeking Alpha
CervoMed Shares Rise 15% on FDA's Orphan Drug Designation for Neflamapimod - Marketscreener.com
CervoMed announces ODD granted to neflamapimod by U.S. FDA - TipRanks
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia - The Manila Times
FDA grants Orphan Drug status to CervoMed's dementia drug - Investing.com
CervoMed Announces Orphan Drug Designation Granted to - GlobeNewswire
CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for - EIN News
CRVO (CervoMed) Profitability Rank : 1 (As of Sep. 2024) - GuruFocus.com
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):